Delivery Order SPE2DB20D2014-SPE2DB25FB81R
- Not listed
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $28,637.24 by the Defense Logistics Agency (DLA) on July 25, 2025, for the supply of Restasis 0.05% Eye Emulsion in 60-count units. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 28, 2025. The contract will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $8,098.45 to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Restasis 0.05% Eye Emulsion in 60-unit quantities. The contract employs firm fixed price terms and is not set-aside, indicating it was competitively awarded. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is a child contract executed under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Restasis 0.05% Eye Emulsion in 60-count units, with a contract ceiling value of $22,836.31. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award selection. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of August 21, 2025. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Restasis 0.05% Eye Emulsion in quantities of 30 units, with a firm fixed price ceiling value of $2,716.92. This is a non-set-aside award with an ultimate completion date of August 11, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a continuation of the company's extensive...
- Amerisourcebergen Drug Corporation, a division of Amerisourcebergen Corporation, has been awarded a $9,993.83 firm fixed price delivery order contract by the Defense Logistics Agency Troop Support Medical to provide 60 units of Restasis 0.05% eye emulsion. Performance will take place in Conshohocken, Pennsylvania over one day in late June 2023. The Defense Logistics Agency Troop Support Medical supports the medical supply needs of the U.S. Department of Defense. This delivery order was issued...
- The Defense Logistics Agency awarded a delivery order valued at $35,696.28 to AmerisourceBergen Drug Corp for the supply of Restasis 0.05% Eye Emulsion in 60-unit quantities. This competitively awarded, firm fixed price delivery order has an ultimate completion date of July 11, 2025, and represents a non-set-aside procurement. The award to AmerisourceBergen's corporate office, located in Conshohocken, Pennsylvania, reflects the company's established role as a critical pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Restasis 0.05% eye emulsion in 60-count packaging, with a contract ceiling value of $2,658.60. This is a firm fixed-price delivery order with no set-aside designation, utilizing competitive procurement procedures. The order is scheduled for completion by September 29, 2025, and will be fulfilled from the contractor's Conshohocken, Pennsylvania location, where...
- Amerisourcebergen Drug Corporation, a division of Amerisourcebergen Corporation, has been awarded a $1,749 firm fixed price delivery order by the Defense Logistics Agency Troop Support Medical to supply 4561491713 units of Restasis 0.05% eye emulsion. Performance will take place in Conshohocken, Pennsylvania over one day in mid-July 2023. The Defense Logistics Agency Troop Support Medical supports the Department of Defense by procuring pharmaceuticals and medical supplies. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $18,550.26 to AmerisourceBergen Drug Corp for RESTASIS 0.05% Eye Emulsion (60 count) on September 11, 2025, with an ultimate completion date of September 12, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's...
- This delivery order, issued on August 22, 2025, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, awards $2,584.16 for the supply of RESTASIS 0.05% Eye Emulsion in 30-unit quantities. The contract employs firm fixed pricing and carries an ultimate completion date of August 25, 2025. This award is not set-aside and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.9 million and...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FB81RDelivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order contract by the Defense Logistics Agency (DLA) on May 2, 2025, for the supply of Restasis 0.05% Eye Emulsion in 30-count units. This firm fixed price delivery order, valued at $1,117.80, represents a non-set-aside competitive award and is scheduled for completion by May 5, 2025. The contract will be performed at the vendor's Corporate Office location in Conshohocken, Pennsylvania, and serves the military healthcare supply chain managed by DLA. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. This prime IDC enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including support for the Defense Health Agency and U.S. Coast Guard. The contract reflects DLA's ongoing procurement through its pharmaceutical prime vendor program, which leverages competitive awards to provide efficient access to brand-name and generic medications across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 5/2/25 |